)
NeOnc Technologies Holdings (NTHI) investor relations material
NeOnc Technologies Holdings Proxy filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Annual meeting scheduled for August 14, 2026, with virtual participation and voting options available for shareholders.
Four main proposals: election of two Class I directors, amendment to the 2023 Equity Incentive Plan, ratification of the independent auditor, and potential adjournment of the meeting.
Record date for voting is June 15, 2026, with 25,931,865 shares of common stock outstanding.
Voting matters and shareholder proposals
Proposal One: Elect two Class I directors (Victoria Medvec, Ph.D. and Steven L. Giannotta, M.D.) for a three-year term ending in 2029.
Proposal Two: Amend the 2023 Equity Incentive Plan to add 1,000,000 shares and provide annual increases of 20% of outstanding shares from 2027 to 2033.
Proposal Three: Ratify CBIZ CPAs P.C. as independent registered public accounting firm for fiscal year ending December 31, 2026.
Proposal Four: Approve adjournment of the meeting if necessary to solicit additional proxies or establish a quorum.
Board recommends voting FOR all proposals.
Board of directors and corporate governance
Board consists of seven members divided into three classes with staggered three-year terms.
Majority of directors are independent per Nasdaq standards; regular executive sessions planned for independent directors.
Three standing committees: Audit, Compensation, and Nominating & Corporate Governance, all comprised of independent directors.
Board held three meetings in 2025; committee attendance and governance guidelines in place.
Director nomination process allows for shareholder nominations with specific advance notice requirements.
- Direct listing on Nasdaq for a biotech with early-stage brain cancer drugs and high capital needs.NTHI
Registration filing6 Jul 2026 - Direct listing of CNS-focused biotech with no commercial revenue, ongoing losses, and exclusive IP.NTHI
Registration filing6 Jul 2026 - Biopharma advancing brain cancer therapies faces high clinical, financial, and regulatory risks.NTHI
Registration filing6 Jul 2026 - Direct listing registers 2.1M shares for resale; early-stage pipeline, high risk, and capital needs.NTHI
Registration filing6 Jul 2026 - Biotech with novel brain cancer therapies in clinical trials, high losses, and ongoing financing needs.NTHI
Registration filing6 Jul 2026 - Clinical-stage biotech registers shares for resale amid ongoing losses and dilution risks.NTHI
Registration filing6 Jul 2026 - Q3 net loss surged to $8.6M as clinical progress and new funding offset high expenses.NTHI
Q3 20256 Jul 2026 - Biopharma firm seeks up to $50M via equity line, advancing brain cancer drugs amid high losses.NTHI
Registration filing6 Jul 2026 - Biotech seeks $300M to advance brain cancer therapies, facing high risk and no current revenue.NTHI
Registration filing6 Jul 2026 - Q1 2025 net loss surged to $38M amid high expenses and cash burn, raising going concern risks.NTHI
Q1 20256 Jul 2026
Next NeOnc Technologies Holdings earnings date
Next NeOnc Technologies Holdings earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Explore our global coverage